SILO — Silo Pharma, Inc.
Is SILO overbought or oversold? Here is the current MarketMoodz read.
Silo Pharma, Inc. (SILO) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Biotechnology) last closed at $1.55. The rating moved from Overbought to Oversold on November 17, 2026.
- Public ratingOversold (as of November 17, 2026)
- Last close$1.55
- Last changeMoved from Overbought to Oversold on November 17, 2026
- SectorHealthcare
- IndustryBiotechnology
See all oversold Healthcare stocks →
AI analysis
Silo Pharma, Inc. is a small-cap, early-stage life-sciences issuer with upside tied to discrete clinical or regulatory catalysts and downside tied to financing, trial outcomes, and low liquidity. Current market tone is biased toward larger-cap, defensive pharmaceutical names and away from speculative micro-cap biotech, which could limit near-term investor appetite. Key drivers to monitor are cash runway and financing plans, timing and readouts of any clinical programs or partnerships, and any new SEC filings that clarify financials. The company faces typical small-biotech execution and regulatory risks, and potential dilution remains a primary concern if non-dilutive capital is unavailable. Near-term price movement is likely to be event-driven and volatile until clearer operational or financial visibility emerges.
Key factors
- Early-stage biopharma profile with a small-cap balance sheet and limited publicly available financial disclosures
- Pipeline optionality: upside from successful clinical or regulatory milestones, which could re-rate valuation materially
- Market environment favors large-cap, defensive pharma names and may reduce speculative capital flows into micro-cap biotech
- Potential access to non-dilutive financing is uncertain; convertible-debt dynamics in the sector increase dilution risk for mid-/small-caps
- Low liquidity and retail-driven intraday moves can produce elevated volatility relative to larger healthcare names
- No major recent filings or widespread social sentiment data available to validate near-term market conviction
Risks
- Limited cash runway or need for dilutive financing could materially depress equity value
- Clinical trial failure or regulatory setbacks that remove key value drivers
- High share-price volatility and low liquidity, amplifying downside on negative news or broader risk-off sessions
- Competitive pressure from larger pharma/biotech with deeper resources and faster commercialization capabilities
- Adverse sector dynamics (rotation to large-cap pharma, tightening risk appetite) reducing capital availability
- Lack of transparent, recent financial reporting increases information asymmetry for investors
- Execution risk in business development, partnerships, or commercialization planning
See today's live rating, score and targets
Members see the live hourly rating for SILO — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.